Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001197020Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE TESTSubmission Contact InformationIs this a Live of the second secon

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Securities
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	1666	39351.00	137422131	09/15/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	5	Nature of Acquisition	Name of Person from	Is this	 Amount of Securities		Nature of Payment *
Ciuos	ricquireu	Transaction			Acquired	1 uyment	i uj ment

Denali Therapeutics Inc. 001-38311 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CALIFORNIA 94080 (650) 866-8548 SATO VICKI L

		Whom Acquired	a Gift?		
Common	06/02/2023 Restricted Stock Lapse	Denali Therapeutics Inc.		1666	06/02/2023 Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of	Amount of Securities Sold	Gross Proceeds
VICKI L SATO 161 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080	Denali Therapeutics Inc.	06/28/2023 16	66	49712.00
VICKI L SATO 161 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080	Denali Therapeutics Inc.	07/17/2023 16	66	49309.00
VICKI L SATO 161 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080	Denali Therapeutics Inc.	08/15/2023 16	66	40477.00

144: Remarks and Signature

Remarks	
Date of Notice	09/15/2023
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/27/2023
ATTENTION:	

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. Signature

VICKI L SATO

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)